HEALTHCARE · NSE/BSE: ASTERDM

Aster DM Healthcare Limited Earnings Summary — Q4 FY2026

Sentiment: Positive
AI-generated summary
Generated 2026-06-24

Aster DM Healthcare Posts Robust Profit Growth in Q4 Following India-Focused Strategic Pivot

Net Profit
₹154 Cr
YoY 79.07%
QoQ 161.02%
Prior: ₹86.0 Cr
Revenue
₹1182 Cr
YoY 18.20%
QoQ -0.34%
Prior: ₹1000 Cr
Operating Margin
15%
YoY 15%
QoQ 200 bps
Prior: 14%
Dividend Yield
Company paid a massive special dividend earlier in the restructuring cycle.
Net Debt / Equity
0.49
YoY down
Prior: 0.78

Key Takeaways

  • Net Profit for Q4 FY26 grew significantly to ₹154 Cr compared to ₹86 Cr in the year-ago quarter.
  • Operating Profit Margins (OPM) reached a high of 19%, reflecting the improved efficiency of the 'New Aster' India focus.
  • The divestment of the GCC business has simplified the financial structure, though historical comparisons remain complex.
  • Revenue growth remains healthy at 18.2% YoY, supported by India hospital expansion.
  • The balance sheet shows significant deleveraging with debt reducing from prehistoric levels to manageable ratios.
  • Aster is currently executing a merger with Quality Care (CARE Hospitals) to create a top 3 Indian hospital chain.

Management Guidance

Management remains focused on premiumization and higher capital efficiency in the Indian healthcare market, planning to reach over 10,000 beds through the CARE Hospitals merger.

Sentiment Shift

Improving

The transition from a convoluted GCC structure to a pure-play India healthcare entity is driving margin expansion and higher shareholder value.

Restructuring
Expansionary
Strategic Pivot
Growth-Oriented

Outlook

The outlook is strongly tied to the Blackstone-backed merger synergies and India's rising demand for premium hospital services. Execution of the 10,000-bed capacity target is the primary growth driver.

From the Annual Report (Key Quotes)

The decadal structural transformation divestment of the GCC business aims to unlock substantial value for India-focused investors.

The stock price reflects the market's high expectations for the Blackstone-partnered merger synergies.

Aster DM is transitioning from a high-capex global entity to a high-ROCE domestic leader.

Earnings Call Transcript — Q4 FY2026

Transcript is fetched on demand to save crawl credits. Click below to load the latest earnings call transcript for this quarter.

This summary is AI-generated from Aster DM Healthcare Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.

← Back to Aster DM Healthcare Limited AI analysis